Regeneron's Schleifer touts Eylea's growth as he beats a forecast
This article was originally published in Scrip
Executive Summary
Leonard Schleifer earned a reputation as a CEO who under promises and over delivers. So when the Regeneron Pharmaceuticals chief says he sees a very large growth potential with his company’s eye drug Eylea, investors take note.